.jpg "David F. Jarrard, MD photo")
Professor
University of Wisconsin
Dr Jarrard is a tenured Professor, Vice Chair of Urology and Deputy Director for the UW Carbone Cancer Center at the University of Wisconsin. He completed a Urology residency at the University of Chicago and Urologic Oncology fellowship at Johns Hopkins Hospitals. He currently serves on prostate cancer guidelines panels for the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA). AUA service includes Chair of the Research, Education and Conferences Committee and Past-President of the AUA North Central Section. He serves on the Board of Directors for the Society for Urologic Oncology (SUO), is a Past-President for the Society for Basic Urologic Research and Past-President of the Society of Academic Urologists (SAU) a group that oversees the residency match and academic affairs. He is an elected member of the American Association of Genitourinary Surgeons.
Dr Jarrard’s clinical work concentrates on advanced Urologic Oncology and improving cancer detection and outcomes. He serves as the urology co-PI on the paradigm shifting CHAARTED trial of docetaxel and ADT for metastatic HSPC, and on other trials in chemoprevention and advanced prostate cancer management. He is the PI of the UW Prostate Cancer SPORE (P50) and has active basic science and translational research interests supported through the NIH (R01) and the Department of Defense Prostate Cancer Research Programs examining epigenetic factors underlying prostate cancer progression and novel approaches to treating advanced disease. Recent studies include the recognition that androgen removal, a common treatment in advanced prostate cancer, when combined with agents targeting unique epigenetic and metabolic changes can improve cancer outcomes. Awards include the SBUR Young Investigator and Distinguished Service Awards, Castle Connolly ‘Top Doctors’, ‘Best Doctor in America™’ and the SUO Distinguished Service Award. Dr. Jarrard has published numerous chapters, articles and abstracts in the field of prostate cancer.
Disclosure information not submitted.
Saturday, April 29, 2023
4:00 PM – 6:00 PM CST